Friday 6 November 2026
Export CAPS’s income statement to Excel — free account
Capstone Therapeutics Corp.
CAPS Basic Materials Building Materials
Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024.
- Revenue
- +67.1%
- EPS
- +15.4%
- Free cash flow
- +73.4%
- Total debt
- +45.9%
Quarter to June 2026, against a year earlier
1.86
0.04
−2.11%
Follow CAPS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (114.39%) | (112.23%) | (468.45%) | (56.01%) |
+8 more TTM periods Free account |
|
| (41.47%) | (40.41%) | (44.49%) | (21.23%) | ||
ROIC |
(17.20%) | (18.84%) | (19.57%) | (3.84%) | |
Return on Tangible Assets |
(1,286.95%) | (3,886.93%) | (1,014.10%) | (789.20%) | |
Average Days of Receivables |
56.80 | 48.77 | 37.87 | 47.10 | |
Free Cash Flow per Share |
(9.05) | (16.31) | (25.59) | (6.49) | |
Free Cash Flow |
(3.81) | (5.07) | (4.53) | (1.23) | |
Capital Expenditures |
(0.21) | (0.13) | (0.12) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(10.00%) | (13.51%) | (12.41%) | (2.62%) | |
Accounts Receivable Turnover |
8.11 | 9.04 | 12.30 | 0.00 | |
Accounts Payable Turnover |
8.64 | 6.91 | 8.74 | 11.14 | |
Inventory Turnover |
3.46 | 2.81 | 2.70 | 0.00 | |
Average Days of Payables |
55.31 | 64.82 | 50.14 | 57.20 | |
Days of Inventory on Hand |
133.09 | 168.20 | 172.56 | 127.10 | |
Tax Rate |
0.03 | 0.03 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
30.22% | 31.17% | 30.66% | 26.68% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1.73) | (2.47) | (2.83) | (1.68) | |
Operating CF/Net income |
0.16 | 0.23 | 0.20 | 0.19 | |
Depreciation/Fixed assets |
2.24 | 1.50 | 1.23 | 0.32 | |
Capex/Depreciation |
(0.05) | (0.04) | (0.05) | (0.04) | |
Revenue per Share |
143.10 | 166.13 | 264.57 | 235.61 | |
Operating CF per Share |
(8.55) | (15.87) | (24.90) | (6.38) | |
Capex per Share |
(0.51) | (0.43) | (0.69) | (0.11) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026